Zinc-based metal-organic frameworks as efficient carriers for anticancer drug to reduce toxicity and increase efficacy

IF 9.6 1区材料科学 Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY

Rare Metals Pub Date : 2024-08-12 DOI:10.1007/s12598-024-02928-x

Dong-Wei Ma, Jing-Sheng Lu, Xiang-Xin Cao, Yan-Wei Cheng, Gang Wang, Zi-Qian Zhang, Bo-Cheng Chen, Ning Lin, Qing Chen

{"title":"Zinc-based metal-organic frameworks as efficient carriers for anticancer drug to reduce toxicity and increase efficacy","authors":"Dong-Wei Ma, Jing-Sheng Lu, Xiang-Xin Cao, Yan-Wei Cheng, Gang Wang, Zi-Qian Zhang, Bo-Cheng Chen, Ning Lin, Qing Chen","doi":"10.1007/s12598-024-02928-x","DOIUrl":null,"url":null,"abstract":"<div><p>The rational design of a specific co-drug delivery platform that can address the unavoidable resistance, toxic side effects and low targeting efficiency of traditional cancer treatments is of great meaningful. Herein, Zn-based MOF-zeolitic imidazole framework-90 (ZIF-90) was selected as the drug delivery carrier, with the cancer therapeutic drug mercaptopurine (6-MP) and glucose oxidase (GOD) as the drug models, hyaluronic acid (HA) was used for protection and targeted delivery, which designed and fabricated an intelligent drug delivery platform (6-MP@ZIF-90@GOD@HA). This platform aims to reduce the toxic side effects of 6-MP and enhance its efficacy while improving the targeting ability of GOD, thereby further enhancing the treatment outcome. Notably, results from both in vitro and in vivo experiments demonstrate that the targeted synergistic chemo/reactive oxygen species (ROS)-mediated/starvation therapy inhibited the cancer cell growth while reducing the chemotherapy toxicity, which provides new possibilities for the development of more precise and effective treatment strategies.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":749,"journal":{"name":"Rare Metals","volume":"43 10","pages":"5152 - 5163"},"PeriodicalIF":9.6000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rare Metals","FirstCategoryId":"88","ListUrlMain":"https://link.springer.com/article/10.1007/s12598-024-02928-x","RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

The rational design of a specific co-drug delivery platform that can address the unavoidable resistance, toxic side effects and low targeting efficiency of traditional cancer treatments is of great meaningful. Herein, Zn-based MOF-zeolitic imidazole framework-90 (ZIF-90) was selected as the drug delivery carrier, with the cancer therapeutic drug mercaptopurine (6-MP) and glucose oxidase (GOD) as the drug models, hyaluronic acid (HA) was used for protection and targeted delivery, which designed and fabricated an intelligent drug delivery platform (6-MP@ZIF-90@GOD@HA). This platform aims to reduce the toxic side effects of 6-MP and enhance its efficacy while improving the targeting ability of GOD, thereby further enhancing the treatment outcome. Notably, results from both in vitro and in vivo experiments demonstrate that the targeted synergistic chemo/reactive oxygen species (ROS)-mediated/starvation therapy inhibited the cancer cell growth while reducing the chemotherapy toxicity, which provides new possibilities for the development of more precise and effective treatment strategies.

Graphical abstract

Abstract Image

查看原文本刊更多论文

锌基金属有机框架作为抗癌药物的高效载体，可降低毒性并提高疗效

针对传统癌症治疗不可避免的耐药性、毒副作用和低靶向效率等问题，合理设计特定的联合给药平台具有重要意义。本文选择了Zn基MOF-唑基咪唑框架-90（ZIF-90）作为给药载体，以癌症治疗药物巯基嘌呤（6-MP）和葡萄糖氧化酶（GOD）为药物模型，以透明质酸（HA）作为保护和靶向给药，设计并制备了一种智能给药平台（6-MP@ZIF-90@GOD@HA）。该平台旨在减少 6-MP 的毒副作用，提高药效，同时改善 GOD 的靶向能力，从而进一步提高治疗效果。值得注意的是，体外和体内实验结果表明，靶向协同化疗/活性氧（ROS）介导/饥饿疗法在抑制癌细胞生长的同时降低了化疗毒性，这为开发更精确、更有效的治疗策略提供了新的可能性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rare Metals 工程技术-材料科学：综合

CiteScore

12.10

自引率

12.50%

发文量

2919

审稿时长

2.7 months

期刊介绍： Rare Metals is a monthly peer-reviewed journal published by the Nonferrous Metals Society of China. It serves as a platform for engineers and scientists to communicate and disseminate original research articles in the field of rare metals. The journal focuses on a wide range of topics including metallurgy, processing, and determination of rare metals. Additionally, it showcases the application of rare metals in advanced materials such as superconductors, semiconductors, composites, and ceramics.